The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

with the resulting molecules fully retaining the biological properties of their parental monoclonal antibodies without the need to significantly modify the structure of the bispecific antibody.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Chinese biotechs InnoCare Pharma and KeyMed Biosciences have sold the international rights to a clinical-stage bispecific antibody to a new company created by RTW Investments for $17.5 million in ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...